三生国健第二代创新优构体IL-17抑制剂-益赛拓®在京东健康全网首发

京东健康黑板报
Mar 07

3月7日,三生制药旗下自主研发的1类创新药安沐奇塔单抗注射液(商品名:益赛拓®)在京东健康全网独家首发。作为一款全新“第二代”优构体IL-17抑制剂,益赛拓®以其快效强效、极低免疫原性和长达8周的给药间隔,为银屑病患者带来了“稳定控病情、轻松过日子”的全新治疗选择。银屑病是一种慢性、复发性、免疫介导的全身性炎症性疾病,由于疾病无法根治且需长期管理,如何实现皮损的深度清除并维持长期疗效,是临床面临的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10